The frequent EGFR mutations identified in this cohort suggest an alternative therapeutic targeting avenue where lessons learnt from the treatment of lung cancer (the cancer type with the highest frequency of EGFR mutations detected) can be applied. The gene discussed is EGFR; the disease is lung carcinoma.